Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

withdrawn3100%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_2

Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

NCT06258499
withdrawnphase_2

Multiregion BHA in Open Tibia Fractures

NCT04056429
withdrawnphase_3

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

NCT03826784

Clinical Trials (3)

Showing 3 of 3 trials
NCT06258499Phase 2

Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

Withdrawn
NCT04056429Phase 2

Multiregion BHA in Open Tibia Fractures

Withdrawn
NCT03826784Phase 3

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
3